A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
Study sponsor: Novavax
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-04-10Actual
Enrollment · participants33000Actual
Source updated2023-12-21Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.